Our findings indicate that the novel miR‐32533/CREB5 signaling may serve as a potential therapeutic target for ameliorating Aβ‐elicited cognitive impairment by reducing Aβ production, oxidative stress, and neuroinflammation in AD. The gene discussed is CREB5; the disease is Cognitive impairment.